← Eikon Therapeutics, Inc. (EIKN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Eikon Therapeutics, Inc. (EIKN)
Biological Products, (No Diagnostic Substances) · market cap $453M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Eikon Therapeutics (EIKN) is a clinical-stage oncology company with a market cap of ~$522M and a lead asset, EIK1001, in Phase 3 for advanced melanoma. The company carries $161.2M in cash but a critically short runway of ~5.4 months, creating acute near-term financing risk alongside a pipeline spanning multiple Phase 2 oncology programs.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2027-06-01 (est.)Phase 2 · IMP1734imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EIK1004-001 (IMP1707-001) | Phase 2 | Advanced Solid Tumors |
| IMP1734 | Phase 2 | Advanced Solid Tumor |
| EIK1005 | Phase 2 | Advanced Solid Tumors |
| EIK1001 | Phase 3 | Advanced Melanoma |
| BDB001 | Phase 2 | Tumor, Solid |
| Paclitaxel + Carboplatin | Phase 3 | Non Small Cell Lung Cancer (Squamous or Non Squamous) |
Price & technical context
3-month
-40.9%
6-month
-26.5%
12-month
—
52-wk range
$7.41–$16.26
vs 50-day MA
-24.6%
vs 200-day MA
—
Realized vol
90.3%
Max drawdown
-54.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EIKN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.